Dr. Philip Schein is President of the Schein Group, Inc., which provides consulting services to the pharmaceutical industry, and is the former Chairman and CEO of US Bioscience, where he took three drugs through development and regulatory approval in the United States, Europe, and Canada, including the radiation protection drug, Ethyol. Schein has held major positions in the field of medical oncology, serving as President of the American Society of Clinical Oncology, and has chaired the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors for the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. Schein also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-U.S., French-U.S., and Pan American Health Organization-U.S. Agreements on Cancer Research.
Schein is widely regarded as a leading international authority on the treatment of cancer, authoring more than 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents. He has received numerous scientific and medical awards, including the Harvey W. Wiley Medal from the U.S. Food and Drug Administration and the Wainwright Award for Excellence in Medical Education and serves on numerous biotechnology and pharmaceutical scientific advisory boards.
Schein received his B.A. in biological science from Rutgers University and his M.D. from Upstate Medical University, and he holds multiple honorary doctorates.